Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
N-Acetylcysteine in COVID-19
NCT05658549Phase 2Completed
- Sponsor
- Universitas Sebelas Maret
- Start
- May 2021
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of acetylcysteine in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Universitas Sebelas Maret. Primary endpoints: Neutrophil to Lymphocyte Ratio at 7 days and Length of Stay. Started May 2021; status: completed.
02
Drugs
acetylcysteine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05658549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05658549.